» Articles » PMID: 34427717

Patterns of Care Analysis for Salivary Gland Cancer: A survey Within the German Society of Radiation Oncology (DEGRO) and Recommendations for Daily Practice

Overview
Specialties Oncology
Radiology
Date 2021 Aug 24
PMID 34427717
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Salivary gland cancer (SGC) is rare and a heterogeneous type of cancer. Prospective randomized trials are lacking. No guideline focusing on standard procedures of radiotherapy (RT) in the treatment of SGC exists. Therefore, we surveyed the members of the German Society of Radiation Oncology (DEGRO) to gain information about current therapeutic strategies of SGC.

Methods: An anonymous questionnaire was designed and made available on the online platform umfrageonline.com. The corresponding link was sent to all DEGRO members who provided their user data for contact purposes. Alternatively, a PDF printout version was sent. Frequency distributions of responses for each question were calculated. The data were also analyzed by type of institution.

Results: Sixty-seven responses were received, including answers from 21 university departments, 22 non-university institutions, and 24 radiation oncology practices. Six participants reported that their departments (practice: n = 5, non-university hospital: n = 1) did not treat SGC, and therefore the questionnaire was not completed. Concerning radiation techniques, target volume definition, and concomitant chemotherapy, treatment strategies varied greatly among the participants. Comparing university vs. non-university institutions, university hospitals treat significantly more patients with SGC per year and initiated more molecular pathological diagnostics.

Conclusion: SGC represents a major challenge for clinicians, as reflected by the inhomogeneous survey results regarding diagnostics, RT approaches, and systemic therapy. Future prospective, multicenter clinical trials are warranted to improve and homogenize treatment of SGC and to individualize treatment according to histologic subtypes and risk factors.

Citing Articles

Survival benefit added by adjuvant chemotherapy in adenoid cystic carcinoma of salivary gland.

An N, Li Y Sci Rep. 2024; 14(1):25746.

PMID: 39468317 PMC: 11519500. DOI: 10.1038/s41598-024-77296-8.


Platinum-based adjuvant chemoradiotherapy versus adjuvant radiotherapy in patients with head and neck adenoid cystic carcinoma.

Qiu Z, Wu Z, Zhou X, Lin M, Su Y, Tao Y J Cancer Res Clin Oncol. 2024; 150(4):195.

PMID: 38625410 PMC: 11021222. DOI: 10.1007/s00432-024-05719-0.


Omission of radiotherapy to lymph node level III in patients with cN0 adenoid cystic carcinoma of the major salivary gland: a single center experience.

Qiu Z, Wu Z, Zhou X, Tao Y, Su Y Radiol Med. 2024; 129(2):335-345.

PMID: 38308063 DOI: 10.1007/s11547-024-01763-5.


Survey in radiation oncology departments in Germany, Austria, and Switzerland: state of digitalization by 2023.

Janssen S, El Shafie R, Grohmann M, Knippen S, Putora P, Beck M Strahlenther Onkol. 2023; 200(6):497-506.

PMID: 38052968 PMC: 11111513. DOI: 10.1007/s00066-023-02182-7.


Deep learning for automatic head and neck lymph node level delineation provides expert-level accuracy.

Weissmann T, Huang Y, Fischer S, Roesch J, Mansoorian S, Ayala Gaona H Front Oncol. 2023; 13:1115258.

PMID: 36874135 PMC: 9978473. DOI: 10.3389/fonc.2023.1115258.


References
1.
Mendenhall W, Morris C, Amdur R, Werning J, Hinerman R, Villaret D . Radiotherapy alone or combined with surgery for adenoid cystic carcinoma of the head and neck. Head Neck. 2004; 26(2):154-62. DOI: 10.1002/hed.10380. View

2.
van Boxtel W, Locati L, van Engen-van Grunsven A, Bergamini C, Jonker M, Fiets E . Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma. Eur J Cancer. 2019; 110:62-70. DOI: 10.1016/j.ejca.2018.12.035. View

3.
Andreoli M, Andreoli S, Shrime M, Devaiah A . Radiotherapy in parotid acinic cell carcinoma: does it have an impact on survival?. Arch Otolaryngol Head Neck Surg. 2012; 138(5):463-6. DOI: 10.1001/archoto.2012.226. View

4.
Lloyd S, Yu J, Wilson L, Decker R . Determinants and patterns of survival in adenoid cystic carcinoma of the head and neck, including an analysis of adjuvant radiation therapy. Am J Clin Oncol. 2010; 34(1):76-81. DOI: 10.1097/COC.0b013e3181d26d45. View

5.
Amini A, Waxweiler T, Brower J, Jones B, McDermott J, Raben D . Association of Adjuvant Chemoradiotherapy vs Radiotherapy Alone With Survival in Patients With Resected Major Salivary Gland Carcinoma: Data From the National Cancer Data Base. JAMA Otolaryngol Head Neck Surg. 2016; 142(11):1100-1110. DOI: 10.1001/jamaoto.2016.2168. View